Launch of DestroCell in Tehran Marks a New Era in Cell Therapy for Iran and Beyond
On Thursday morning, October 24, 2024, doctors, researchers, and other distinguished guests gathered at Tehran’s Spinas Palace Hotel for the official launch of DestroCell, Iran’s first allogeneic cell therapy product approved by the Food and Drug Organization of Iran.
Taskin Bioregeneration Announces Launch of Phase II/III Clinical Trials for DesRep
Tehran, October 2024 – Taskin Bioregeneration, a pioneering company in regenerative medicine and cell therapy, is proud to announce the launch of Phase II/III clinical trials for DesRep, an advanced treatment specifically designed to address chronic wounds and diabetic foot ulcers. This trial comes after receiving ethical committee approval and will be conducted in collaboration with Tehran University of Medical Sciences and Jihad Branch of Tehran University.
Job Opportunity – Researcher Positions at Taskin Bioregeneration
Taskin Bioregeneration is a leading company in the field of cell and gene therapy. We are currently conducting clinical trials focused on innovative treatments that harness the power of regenerative medicine.
About Us
At Taskin Bioregeneration, we are pioneers in revolutionizing healthcare through cutting-edge advancements in cell and gene therapy. With a rich history deeply rooted in the medical landscape of Iran, our journey began with the inception of Taskin Hospital in Rafsanjan, supported by charitable endeavors.
News
DestroCell Offers New Hope for Steroid-Resistant GVHD Treatment
DestroCell is a revolutionary placenta-derived stromal cell therapy with powerful immunomodulatory effects, targeting acute inflammatory diseases and autoimmune disorders.
Pipe Line
At Taskin Bioregeneration, our dedication to pioneering cell and gene therapies drives us to push the boundaries of medical science. Our pipeline showcases a range of innovative therapies, each aimed at addressing critical health conditions. Here’s a closer look at our current projects
